SYRE vs. KRYS, SWTX, BHVN, RXRX, PTCT, OGN, RARE, ALVO, RNA, and ADMA
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Avidity Biosciences (RNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs.
Spyre Therapeutics (NASDAQ:SYRE) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Krystal Biotech has a net margin of 30.69% compared to Spyre Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat Spyre Therapeutics' return on equity.
80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Spyre Therapeutics has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Krystal Biotech has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Krystal Biotech had 25 more articles in the media than Spyre Therapeutics. MarketBeat recorded 32 mentions for Krystal Biotech and 7 mentions for Spyre Therapeutics. Krystal Biotech's average media sentiment score of 0.75 beat Spyre Therapeutics' score of 0.61 indicating that Krystal Biotech is being referred to more favorably in the news media.
Krystal Biotech received 275 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 67.51% of users gave Krystal Biotech an outperform vote.
Spyre Therapeutics currently has a consensus price target of $54.83, suggesting a potential upside of 157.55%. Krystal Biotech has a consensus price target of $210.00, suggesting a potential upside of 11.79%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Spyre Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 2/21/2025 by MarketBeat.com Staff
